AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
AstraZeneca
AstraZeneca
University of Michigan Rogel Cancer Center
Neonc Technologies, Inc.
AstraZeneca
Ruijin Hospital